Bispebjerg Hospital
Copenhagen, Select State, 2400, Denmark
Completed
NCT Number: NCT02558088
Pharmacological Properties of Salmeterol
The objective of the study is to help establish a urinary threshold for salmeterol on the World Anti-doping Agency prohibited list, to avoid supratherapeutic of this substance in competitive sports.
Hence, there is no hypothesis as such.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–45 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 4
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male
- 18-45 years
- Healthy
Exclusion criteria
- Chronic disease
- Smoking
- Habitual use of medicine
- Allergy towards salmeterol
- Unable to exercise on a bike ergometer
Treatment and study plan
Salmeterol
DrugPrimary outcomes
-
Urine concentration of salmeterol
Time frame: 0-24 hours after administration of the study drug
Sponsors and collaborators
Lead sponsor
University of Copenhagen
Other
Registry information
Official study title
Pharmacological Properties of Inhaled Salmeterol in Healthy Trained Males
Important dates
- Study start
- 2014
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Sep 23, 2015
- Registry last updated
- Jan 31, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.